Lungs News and Research

RSS

PCORI awards $2.1M to USF college of nursing to study a new approach for cancer management

The Patient-Centered Outcomes Research Institute (PCORI) has approved a $2.1-million award to the University of South Florida College of Nursing to study "Patient Outcomes of a Self-care Management Approach to Cancer Symptoms: A Clinical Trial." USF Distinguished Professor and Thompson Professor of Oncology Nursing Susan C. McMillan, PhD, ARNP, FAAN, will lead the research project.

4 Jun 2013

Study demonstrates significant mortality rate among non-adhering heart transplant adolescent patients

After receiving an organ transplant, patients must follow a regimented medication routine to maintain the health of their graft (transplanted organ). Failure to do so, known as non-adherence (NA), can result in life-threatening illness.

4 Jun 2013

Diaxonhit, XDx agree to market and perform AlloMap Molecular Expression Testing in Europe

Diaxonhit, the leading French provider of specialty diagnostic solutions, and XDx, Inc., a U.S. molecular diagnostics company focused on non-invasive tests for transplantation and autoimmune disease, announced today that they have entered into a memorandum of agreement for the exclusive license to market and perform AlloMap Molecular Expression Testing (AlloMap) in Europe.

4 Jun 2013

Researchers solve long-standing mystery behind dormant disseminated breast tumor cells

The long-standing mystery behind dormant disseminated breast tumor cells and what activates them after years and even decades of latency may have been solved. Researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) have identified the microenvironment surrounding microvasculature - the small blood vessels that transport blood within tissues - as a niche where dormant cancer cells reside. When these blood vessels begin to sprout, the new tips produce molecules that transform dormant cancer cells into metastatic tumors.

4 Jun 2013

Cardiovascular disease: The leading cause of death in UK

Cardiovascular disease is the leading cause of death in the UK, accounting for a third of all fatalities through illnesses such as stroke and heart disease.

4 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

4 Jun 2013

New tool enables doctors to monitor infections, inflammation and scarring in lungs

Intensive care patients who are on breathing support could be helped by a new tool to enable doctors to see inside their lungs to check for and monitor infections, inflammation and scarring.

4 Jun 2013

Three health education leaders to be honored as 2013 Champions of Health Professions Diversity

Three inspiring leaders in health education will be honored by The California Wellness Foundation as the 2013 Champions of Health Professions Diversity for their successful efforts to improve the health and wellness of California's most underserved communities.

4 Jun 2013

Study: Mutations in gene NTRK1 cause a subset of lung cancers

To the list of oncogenic drivers of lung cancer that includes ALK, EGFR, ROS1 and RET, results of a University of Colorado Cancer Center study presented at ASCO 2013 show that mutations in the gene NTRK1 cause a subset of lung cancers.

4 Jun 2013

Study provides important details for recently identified target in lung adenocarcinoma

In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: rearrangement of the gene RET.

4 Jun 2013

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma at the ASCO Annual Meeting on June 3, 2013.

4 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

New drug shows promising results with manageable side effects for treating melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.

3 Jun 2013

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene are likely to fare better if treated with a targeted therapy than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.

3 Jun 2013

Activ8rlives 2.0 goes live with new self monitoring capabilities for health and wellness

Activ8rlives’ website version 2.0 has now gone live after several months of preparation and testing. Activ8rlives focuses its online self monitoring solutions for health and wellness, which is utilized by families, groups and companies.

3 Jun 2013

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center led by Dr. Antoni Ribas, professor of medicine in the division of hematology-oncology, report preliminary results showing significant antitumor activity with very manageable side effects from a new drug being tested in patients with advanced melanoma, the deadliest form of skin cancer.

3 Jun 2013

Study finds HER2 irregularities in 14 different advanced solid tumors

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes's expression - among them mutations, amplifications, substitutions, and translocations - have been found in 14 different advanced solid tumors.

3 Jun 2013

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting.

3 Jun 2013

LUNGevity Foundation to join with WSA to empower, educate women affected by lung cancer

LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, is proud to join together with The Women Survivors Alliance in an effort to empower, educate and connect women who have been touched by cancer and represent those who have been impacted by lung cancer.

3 Jun 2013

Lungs News and Research

PCORI awards $2.1M to USF college of nursing to study a new approach for cancer management

Study demonstrates significant mortality rate among non-adhering heart transplant adolescent patients

Diaxonhit, XDx agree to market and perform AlloMap Molecular Expression Testing in Europe

Researchers solve long-standing mystery behind dormant disseminated breast tumor cells

Cardiovascular disease: The leading cause of death in UK

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Cancer immunotherapy shows promise in treating patients with metastatic tumors

New tool enables doctors to monitor infections, inflammation and scarring in lungs

Three health education leaders to be honored as 2013 Champions of Health Professions Diversity

Study: Mutations in gene NTRK1 cause a subset of lung cancers

Study provides important details for recently identified target in lung adenocarcinoma

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

New drug shows promising results with manageable side effects for treating melanoma

Lung cancer patients are likely to fare better if treated with targeted therapy than with chemotherapy

Activ8rlives 2.0 goes live with new self monitoring capabilities for health and wellness

Lambrolizumab shows significant antitumor activity in patients with advanced melanoma

Study finds HER2 irregularities in 14 different advanced solid tumors

Sorafenib stops tumor growth, provides effective treatment for thyroid cancer patients

LUNGevity Foundation to join with WSA to empower, educate women affected by lung cancer

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News